Characterization of New PPARγ Agonists: Benzimidazole Derivatives – the Importance of Position 2

Probing SAR: The 1‐(biphenyl‐4‐ylmethyl)‐1H‐benzo[d]imidazole moiety is known to be an essential structural component of telmisartan for PPARγ activation. This study focused on the substituents at position 2 of the benzimidazole in an attempt to optimize PPARγ activation. In particular, the elongation of the alkyl chain and the introduction of an aromatic ring system were studied (shown).

[1]  L. Madsen,et al.  Modulation of rat liver apolipoprotein gene expression and serum lipid levels by tetradecylthioacetic acid (TTA) via PPARalpha activation. , 1999, Journal of lipid research.

[2]  Mitchell A. Avery,et al.  Identification of Telmisartan as a Unique Angiotensin II: Receptor Antagonist With Selective PPARγ–Modulating Activity , 2004, Hypertension.

[3]  P. Dalko,et al.  Stereoselective Synthesis of Quaternary Benzylic Carbons Using C2 Symmetric Imidazolines and Tetrahydrofuran as Electrophile , 1998 .

[4]  B. Spiegelman.  PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. , 1998, Diabetes.

[5]  B. Spiegelman,et al.  International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors , 2006, Pharmacological Reviews.

[6]  R. Gust,et al.  Structure-activity relationship study to understand the estrogen receptor-dependent gene activation of aryl- and alkyl-substituted 1H-imidazoles. , 2007, Journal of medicinal chemistry.

[7]  T. Willson,et al.  The PPARs: from orphan receptors to drug discovery. , 2000, Journal of medicinal chemistry.

[8]  K. Umesono,et al.  A Unified Nomenclature System for the Nuclear Receptor Superfamily , 1999, Cell.

[9]  Bruce A. Johnson,et al.  Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. , 2003, Molecular endocrinology.

[10]  U. Kintscher,et al.  Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. , 2005, Diabetes.

[11]  T. Willson,et al.  Peroxisome proliferator activated receptor agonists. , 1997, EXS.

[12]  U. Kintscher,et al.  Angiotensin Type 1 Receptor Blockers Induce Peroxisome Proliferator–Activated Receptor-γ Activity , 2004, Circulation.

[13]  U. Kintscher,et al.  Characterization of New PPARγ Agonists: Analysis of Telmisartan’s Structural Components , 2009, ChemMedChem.

[14]  J. Berger,et al.  The mechanisms of action of PPARs. , 2002, Annual review of medicine.